News &amp; Updates

What drives condom use among teens?

Condom use during first sexual encounter, intentions to use condoms, and the ability to communicate with the partner about safe sex emerge as the strongest predictors of condom use among teens in the US, as reported in a meta-analysis.

What drives condom use among teens?

Original New Drug Application Approvals by US FDA (16-31 January 2025)

New drug applications approved by US FDA as of 16-31 January 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 January 2025)

MTX plus MMI for Graves’ disease tied to higher discontinuation rate

The addition of low-dose methotrexate (MTX) to methimazole (MMI) shows a higher rate of discontinuation than MMI alone, as well as significant reductions in thyrotropin-related antibodies (TRAb) levels, in patients with Graves’ disease (GD), reveals a study.

MTX plus MMI for Graves’ disease tied to higher discontinuation rate

Dupilumab trumps MTX, cyclosporine in paediatric AD

The use of dupilumab in children with moderate-to-severe atopic dermatitis (AD) results in greater improvements in AD severity, better adherence, and fewer treatment-emergent adverse events (TEAEs) than methotrexate (MTX) or cyclosporine, as shown by 2-year interim results from the PEDISTAD study.

Dupilumab trumps MTX, cyclosporine in paediatric AD

03 Feb 2025

Transdermal microneedle less painful vs intralesional injection in AA

In the treatment of mild-to-moderate patchy alopecia areata (AA), microneedle transdermal delivery of compound betamethasone exhibits similar efficacy as the traditional intralesional injection and a significant reduction in pain, according to a study.

Transdermal microneedle less painful vs intralesional injection in AA

CKM syndrome screening key to addressing its growing challenges

Screening to facilitate early detection and interdisciplinary management is key to incorporating the cardiovascular-kidney-metabolic (CKM) health framework into Hong Kong’s healthcare system in order to address the growing challenges of CKM syndrome.

CKM syndrome screening key to addressing its growing challenges

Add-on tiragolumab improves antitumour response in unresectable HCC

In the treatment of patients with unresectable hepatocellular carcinoma (HCC), the addition of tiragolumab to atezolizumab plus bevacizumab yields meaningful improvements in antitumour response and disease control, according to data from an open-label phase 1b–2 study.

Add-on tiragolumab improves antitumour response in unresectable HCC

Use of APCC in an elderly AHA patient requiring invasive procedures

An 81-year-old female presented to a private hospital with painful right upper arm swelling and bruising in August 2023. There was no history of trauma or contusion other than a minor sprain 2 weeks prior to presentation. There was also no family history of bleeding tendency. The patient had multiple comorbidities: hypertension, hyperlipidaemia, type 2 diabetes (T2D), overweight (body weight, 60 kg; BMI, 25 kg/m²), osteoarthritis of both knees, and vitamin B12 deficiency.

Use of APCC in an elderly AHA patient requiring invasive procedures

03 Feb 2025

Use of an oral ACL inhibitor in two diabetic patients with hypercholesterolaemia and high/very high CV risk

A 62-year-old nonsmoking Chinese man with metabolic syndrome (MES; hypertension, obesity, hypercholesterolaemia) and mild hyperuricaemia presented with type 2 diabetes (T2D; HbA_1c, 8.4 percent) in October 2018. His only baseline medication was candesartan 8 mg QD.

Use of an oral ACL inhibitor in two diabetic patients with hypercholesterolaemia and high/very high CV risk